Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368838 | 0.90 | SMYD2 (0.37) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL18069583 | 0.90 | SMYD2 (0.37) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL702653 | 0.89 | LTA4H (0.42) | SMYD2HTTSMN1; SMN2CYP3A4LTA4H | |
| SCHEMBL5488886 | 0.87 | LTA4H (0.42) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL15426891 | 0.86 | SOAT1 (0.41) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL13284463 | 0.86 | SOAT1 (0.41) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL16888352 | 0.86 | SOAT1 (0.41) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL18724647 | 0.86 | SOAT1 (0.41) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL6276817 | 0.84 | SOAT1 (0.40) | SMYD2HTTSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL708399 | 0.84 | SMYD2 (0.36) | SMYD2HTTSMN1; SMN2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | claimed |
| CN-119604287-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-107445980-B | 3-substituted 5-amino-6H-thiazolo [4,5-d ] pyrimidine-2, 7-dione compounds | 豪夫迈·罗氏有限公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| EP-2370467-B1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RES MUNICH GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| WO-2016115530-A1 | METHOD AND SYSTEM FOR DETERMINING CANCER STATUS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20150361466-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | INV NYLON CHEMICALS AMERICAS, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-20100155121-A1 | SILICA FILM FORMING MATERIAL, SILICA FILM AND METHOD OF MANUFACTURING THE SAME, MULTILAYER WIRING STRUCTURE AND METHOD OF MANUFACTURING THE SAME, AND SEMICONDUCTOR DEVICE AND METHOD OF MANUFACTURING THE SAME | FUJITSU LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7659357-B2 | Precursor organosilicon polymer of 1,2-Bis(dimethylethoxysilyl)ethane, 1,4-bis(dimethylethoxysilyl)benzene, tetraethoxysilane, methyltriethoxysilane, phenyltriethoxysilane; dielectric (DE) films having etching/chemical/moisture resistance; adhesion; low DE constant; minimal wiring delay; high speed | FUJITSU LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-7335671-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-26 | — | — | US | disclosed |
| US-20070026689-A1 | Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same | FUJITSU LIMITED (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, FFAR1, FFAR2 | SMYD2 4556/4885HTT 1316/4885SMN1; SMN2 2586/4885 |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, FFAR1, FFAR2 | SMYD2 4546/4885HTT 1571/4885SMN1; SMN2 2706/4885 |
| US-20150361466-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | ACADM, FADS2, ALKBH3 | SMYD2 451/4885HTT 1145/4885SMN1; SMN2 4771/4885 |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | RICTOR, MTOR, RPTOR | SMYD2 4659/4885HTT 2742/4885SMN1; SMN2 3510/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | SMYD2 3648/4885HTT 1033/4885SMN1; SMN2 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.